Form 4 for TLX Telix Pharmaceuticals Ltd
Accepted 2026-04-01 19:14:36 ET · period of report 2026-03-29 · accession 0001628280-26-022909 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-01 19:14 | 2026-03-29 | TLX | Smith Darren Charlton | Group CFO | M - OptEx | $0.00 | +1,111 | 11.9K | +10% | $0 |
| D | 2026-04-01 19:14 | 2026-03-29 | TLX | Smith Darren Charlton | Group CFO | M - OptEx | $0.00 | -1,111 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-03-29 | M | A | 1,111 | $0.00 | 11,921 | D | — | — | |
| 2 | Derivative | Share Rights | 2026-03-29 | M | D | 1,111 | $0.00 | 0 | D | $0.00 · — to 2028-03-31 | 1,111 Ordinary Shares | (F1) The share rights (SRs) were granted on January 1, 2025 and became vested and exercisable on March 5, 2026. |